Tumor Growth: Avascular and Vascular

3D Simulations

🩺 Medicine · Mathematical Oncology

📅 July 2026⏱ 12 min🟡 Intermediate · Last updated: 3 July 2026

Tumor Growth: Avascular and Vascular

A solid tumor's growth curve is not a simple exponential — it is a story told in two acts. In the first act, a diffusion-limited avascular nodule grows, stalls, and hollows out from within. In the second, it recruits its own blood supply through angiogenesis and growth resumes on an entirely different footing. The mathematics separating these two regimes — logistic and Gompertzian laws, reaction-diffusion oxygen gradients, and the angiogenic switch — is the backbone of modern mathematical oncology and the basis for computational tumor simulations used in drug development.

Written by MySimulator Team · Reviewed by MySimulator Editorial Review

1. From One Cell to a Mass

Cancer begins with a single cell that has accumulated mutations disabling the normal controls on proliferation — inactivated tumor suppressors such as p53 and Rb, activated oncogenes such as KRAS or MYC, and evasion of apoptosis. Left unchecked, that cell divides roughly every 24–48 hours. After around 30 doublings a clone reaches roughly 10⁹ cells — about one gram, or one cubic centimetre, the smallest mass reliably detectable by imaging. Two more doublings and it reaches 10¹⁰–10¹¹ cells, a size commonly associated with clinical symptoms or metastatic spread.

The critical insight of mathematical oncology is that growth rate is not constant across this journey. Early on, nutrients and oxygen diffuse freely from surrounding tissue and cells divide near their maximum biological rate. But diffusion has a hard physical limit — roughly 100–200 μm, about the width of a few hundred cells — beyond which oxygen concentration falls below what mitochondria need. Past that point, growth without a dedicated blood supply becomes self-limiting.

2. Growth Laws: Exponential, Logistic, Gompertz

Three growth laws are commonly used to describe tumor size over time, each a progressively better fit to the empirical deceleration.

Exponential growth (unconstrained): dN/dt = r\cdotN \to N(t) = N₀\cdote^(rt) Logistic growth (carrying capacity K): dN/dt = r\cdotN\cdot(1 - N/K) Growth rate falls linearly as N approaches K. Gompertz growth (best empirical fit for most solid tumors): dN/dt = r\cdotN\cdotln(K/N) Equivalently: N(t) = K\cdotexp[ -ln(K/N₀)\cdote^(-rt) ] Key difference: Gompertz growth decelerates much faster than logistic growth as N grows, because ln(K/N) \to 0 more sharply than (1 - N/K) does not — it produces the characteristic sigmoidal curve with a very long, slow-approaching plateau that matches observed tumor volume-doubling-time data.

Empirically, tumor volume-doubling times lengthen as a tumor grows — a 0.5 cm nodule may double in weeks, while a 5 cm mass of the same histology doubles far more slowly. This deceleration is exactly what the Gompertz equation predicts, and it is why the Gompertz model (introduced by Benjamin Gompertz in 1825 for actuarial mortality, later repurposed for tumor kinetics by Anna Kane Laird in 1964) remains the standard descriptive law in clinical oncology, radiotherapy fractionation planning, and chemotherapy scheduling models.

3. The Avascular Spheroid

Before recruiting blood vessels, a tumor grows as an avascular nodule, experimentally modelled in the lab by the multicellular tumor spheroid (MCTS) — a free-floating ball of cancer cells grown in culture that self-organises into the same layered structure seen in early in-vivo tumors. Spheroids are the workhorse model of avascular tumor biology precisely because their growth is governed almost entirely by diffusion physics rather than blood flow, making them mathematically tractable.

A spheroid's radius R(t) initially grows exponentially, then transitions to roughly linear growth, and finally plateaus at a steady-state radius R∞ typically between 200–500 μm — set by the balance between the proliferating rim and a necrotic core consuming no net volume. This plateau is the direct experimental signature of the diffusion limit described below.

4. Diffusion Limits and the Three Zones

Oxygen transport through avascular tissue obeys a reaction-diffusion equation. At steady state, with consumption rate Γ roughly constant until oxygen is exhausted:

Steady-state diffusion-consumption (spherical symmetry): D\cdot\nabla²c - Γ = 0 D\cdot(1/r²)\cdotd/dr(r²\cdotdc/dr) = Γ Solving with c(R) = c₀ (surface concentration) gives: c(r) = c₀ - (Γ/6D)\cdot(R² - r²) Critical hypoxic radius R_diff (distance oxygen can penetrate before c \to 0), from Krogh's original 1919 capillary analysis: R_diff = \sqrt(6\cdotD\cdotc₀ / Γ) \approx 100-200 μm for O₂ in tissue D (oxygen diffusion coefficient) \approx 1-2 \times 10⁻⁵ cm²/s

This produces the classic three-zone structure of an avascular tumor, visible in histological cross-sections of untreated nodules and spheroids alike:

Proliferating rim (0–100 μm from the surface): Well-oxygenated, actively cycling cells. This thin outer shell drives essentially all net volume growth once the tumor exceeds the diffusion limit — the interior no longer contributes.
Quiescent zone: Cells here survive but exit the cell cycle (G0 arrest) due to marginal oxygen and glucose, remaining viable and able to re-enter proliferation if reoxygenated — the basis for tumor regrowth after debulking surgery.
Necrotic core: Beyond R_diff, cells die from energy failure, releasing damage-associated molecular patterns (DAMPs) that recruit inflammatory cells and, critically, help trigger the angiogenic switch discussed next.

Why this caps growth: Volume scales as R³ but the proliferating shell's volume scales only as R² (surface area × fixed shell thickness) once R exceeds R_diff. The fraction of actively dividing cells therefore falls as 1/R, driving the Gompertzian deceleration and explaining why an untreated avascular nodule cannot exceed roughly 1–2 mm in diameter without new vasculature.

5. The Angiogenic Switch

The transition from a dormant, size-limited avascular nodule to an aggressively growing vascularised tumor is called the angiogenic switch — a concept formalised by Judah Folkman in the 1970s. It is a shift in the local balance between pro- and anti-angiogenic signalling molecules, driven primarily by hypoxia in the tumor's growing necrotic core.

Hypoxia-driven signalling cascade: Low O₂ \to HIF-1α (hypoxia-inducible factor) stabilised \to HIF-1α binds hypoxia-response elements (HREs) \to transcription of VEGF-A ↑ (up to 30-fold) \to also: FGF-2, PDGF, angiopoietin-2, IL-8 ↑ Switch condition (net angiogenic balance B): B = Σ(pro-angiogenic) - Σ(anti-angiogenic) = [VEGF, FGF-2, PDGF, ...] - [thrombospondin-1, angiostatin, endostatin, ...] Switch flips to "on" when B > 0 sustained over the tumor margin.

Under normoxia, HIF-1α is continuously hydroxylated by prolyl hydroxylases and degraded via the von Hippel–Lindau (VHL) ubiquitin pathway. Under hypoxia, hydroxylation stalls, HIF-1α accumulates, and it drives transcription of VEGF-A — the single most important pro-angiogenic factor in tumor biology and the target of drugs such as bevacizumab (Avastin). The angiogenic switch typically occurs once the nodule approaches its diffusion-limited plateau, at roughly 1–2 mm diameter — explaining why the avascular phase, while essential, is usually brief and clinically silent.

6. Angiogenesis: Sprouting New Vessels

Once VEGF concentration crosses a local threshold, nearby endothelial cells lining existing capillaries respond:

Vessel destabilisation: Angiopoietin-2 loosens pericyte contacts and degrades the basement membrane around a parent vessel, priming it to sprout.
Tip cell selection: The endothelial cell with the highest VEGF-receptor (VEGFR-2) signalling becomes a migratory "tip cell" extending filopodia up the VEGF gradient, via Notch/Dll4 lateral inhibition that suppresses neighbouring cells from also becoming tip cells.
Stalk cell proliferation: Cells trailing the tip cell proliferate and elongate, forming a hollow sprout that extends chemotactically toward the tumor.
Anastomosis and lumen formation: Sprouts fuse with neighbouring sprouts or existing vessels, forming closed loops; a lumen opens and blood flow begins, delivering oxygen and nutrients directly into the tumor mass.

The tip-cell migration itself is well described as biased random motion up a chemical gradient — a chemotaxis process modelled with the Keller–Segel framework, closely related to the reaction-diffusion mathematics used for morphogenesis and bacterial chemotaxis elsewhere on this site:

Keller-Segel chemotaxis (endothelial cell density n, VEGF c): \partialn/\partialt = D_n\cdot\nabla²n - \nabla\cdot(χ\cdotn\cdot\nablac) (diffusion - chemotactic drift) \partialc/\partialt = D_c\cdot\nabla²c + production(tumor) - decay\cdotc χ = chemotactic sensitivity coefficient; the drift term -\nabla\cdot(χ\cdotn\cdot\nablac) pulls endothelial cell density up the VEGF gradient, producing branching, tree-like vessel networks rather than straight lines — closely matching observed tumor vasculature.

7. Vascular Growth and Its Chaos

Once perfused, a tumor is no longer diffusion-limited and its growth rate rises sharply — but the vasculature it builds is nothing like healthy tissue. Tumor vessels are:

Structurally abnormal: Tortuous, dilated, unevenly branched, with dead ends and blind loops, lacking the hierarchical arteriole → capillary → venule organisation of normal tissue.
Leaky: Loose endothelial junctions and sparse pericyte coverage allow plasma to leak into the interstitium, raising interstitial fluid pressure — this is the physical basis of the enhanced permeability and retention (EPR) effect exploited by nanoparticle chemotherapy delivery.
Functionally inefficient: Despite dense vascularisation, blood flow is chaotic and intermittent, so paradoxically many vascularised tumors still contain hypoxic regions — a phenomenon called "diffusion-limited" and "perfusion-limited" (or acute) hypoxia coexisting in the same mass.

With a blood supply established, growth is no longer geometrically capped by diffusion and can, in principle, approach exponential rates again — although the Gompertz law continues to fit the overall volume curve well in most clinical series, because new internal hypoxic pockets constantly reproduce a scaled-down version of the avascular limit throughout the growing mass. This nested, self-similar limiting behaviour is one reason Gompertzian kinetics remain such a robust empirical fit across almost all solid tumor types and species, from mouse xenografts to human radiological follow-up data.

8. Simulating Tumor Growth Computationally

Because real tumors cannot be observed continuously in three dimensions inside a living patient, computational models are a core tool in mathematical oncology. Two families dominate:

Continuum (PDE) models: Treat tumor cell density, oxygen, and VEGF as continuous fields governed by coupled reaction-diffusion equations, as shown above. Efficient for large tissue-scale simulations and for fitting to clinical imaging data (MRI-derived tumor volumes).
Agent-based / hybrid models: Track individual cells as discrete agents with rules for division, death, and migration, sitting on a continuum oxygen/VEGF field. These reproduce the sharp proliferating-rim / necrotic-core boundary and the branching vessel morphology far more realistically than pure PDE approaches, at higher computational cost.

Minimal hybrid update rule per timestep, per cell i: 1. Sample local oxygen c_i from diffusion field 2. If c_i > c_prolif: cell may divide (probability \propto r\cdotΔt) 3. Else if c_i > c_death: cell becomes quiescent (no division) 4. Else: cell dies \to removed, contributes necrotic debris 5. Update oxygen field: solve \partialc/\partialt = D\nabla²c - Γ\cdot(live cells) + source(vessels) 6. If VEGF(x) > threshold near a vessel: spawn/extend a tip cell (Keller-Segel chemotaxis step, see above)

These simulations are used to test "what if" scenarios that would be unethical or impossible in patients — for example, predicting how a tumor's growth curve changes under different radiotherapy fractionation schedules, or how resistant subclones emerge and spatially segregate under chemotherapy pressure, long before a single dose is given in a clinical trial.

9. Therapeutic Implications

Every stage of this growth story is a drug target actively used in the clinic today:

Anti-angiogenic therapy: Bevacizumab and other VEGF/VEGFR inhibitors aim to starve the tumor back toward the avascular, diffusion-limited regime — normalising vasculature can paradoxically improve chemotherapy delivery before it cuts off supply entirely.
Fractionated radiotherapy: exploits the fact that well-oxygenated proliferating-rim cells are far more radiosensitive than hypoxic core cells (the oxygen enhancement ratio, OER, is roughly 2.5–3); splitting dose into fractions allows reoxygenation of surviving hypoxic cells between treatments.
Nanoparticle and antibody-drug conjugates: Exploit the leaky, abnormal vasculature (EPR effect) of the vascular growth phase to concentrate drug payload preferentially in tumor tissue.
Metronomic chemotherapy: Low, frequent doses (rather than maximum-tolerated-dose pulses) specifically target proliferating endothelial tip cells, aiming to suppress angiogenesis continuously rather than kill tumor cells directly.

Understanding tumor growth as a two-phase, diffusion-then-perfusion process — rather than a single exponential curve — is what allows oncologists and computational biologists to reason quantitatively about when a tumor is likely to accelerate, and where in its biology a given therapy is actually intervening.